Kymriah
E584153
Kymriah is a pioneering CAR-T cell therapy used to treat certain types of blood cancers by genetically modifying a patient’s own immune cells to target and destroy malignant cells.
All labels observed (4)
| Label | Occurrences |
|---|---|
| Kymriah canonical | 3 |
| Abecma | 1 |
| CAR T-cell therapies | 1 |
| tisagenlecleucel | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T6311256 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Kymriah Context triple: [Novartis, notableDrug, Kymriah]
-
A.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
B.
Keytruda
Keytruda is a widely used immunotherapy cancer drug (pembrolizumab) that works by blocking the PD-1 pathway to help the immune system attack tumors.
-
C.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
D.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
E.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Kymriah Target entity description: Kymriah is a pioneering CAR-T cell therapy used to treat certain types of blood cancers by genetically modifying a patient’s own immune cells to target and destroy malignant cells.
-
A.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
B.
Keytruda
Keytruda is a widely used immunotherapy cancer drug (pembrolizumab) that works by blocking the PD-1 pathway to help the immune system attack tumors.
-
C.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
D.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
E.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
- F. None of above. chosen
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
CAR-T cell therapy
ⓘ
gene therapy medicinal product ⓘ oncology drug ⓘ prescription medicine ⓘ |
| administrationRoute | intravenous infusion ⓘ |
| adverseEffect |
cytokine release syndrome
ⓘ
hypogammaglobulinemia ⓘ infections ⓘ neurotoxicity ⓘ prolonged cytopenias ⓘ |
| ATCCode | L01XL01 ⓘ |
| belongsToCategory | advanced therapy medicinal product ⓘ |
| boxedWarning |
cytokine release syndrome
ⓘ
neurological toxicities ⓘ |
| developer | Novartis ⓘ |
| firstEMAApprovalDate | 2018-08-27 ⓘ |
| firstFDAApprovalDate | 2017-08-30 ⓘ |
| firstIndication | pediatric and young adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia ⓘ |
| firstIndicationRegion |
United States
ⓘ
linked to:
United States of America
|
| hasTradeName | Kymriah ⓘ |
| indication |
adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
ⓘ
adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy ⓘ pediatric and young adult patients with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse ⓘ |
| legalStatusEU | prescription-only ⓘ |
| legalStatusUS | prescription-only ⓘ |
| manufacturingProcess | ex vivo genetic modification of T cells with a lentiviral vector encoding a chimeric antigen receptor ⓘ |
| marketingAuthorizationHolder |
Novartis Pharma AG
ⓘ
linked to:
Novartis
|
| mechanismOfAction | CD19-directed genetically modified autologous T cell immunotherapy ⓘ |
| molecularTarget | CD19 ⓘ |
| notableFeature | first CAR-T cell therapy approved by the US FDA ⓘ |
| patientPopulation |
adult patients
ⓘ
pediatric patients ⓘ young adult patients ⓘ |
| pharmacologicalClass | antineoplastic agent ⓘ |
| regulatoryStatus |
EMA-approved
ⓘ
FDA-approved ⓘ |
| requires | leukapheresis of patient T cells ⓘ |
| requiresMonitoring | hospitalization and monitoring for cytokine release syndrome ⓘ |
| requiresPreconditioning | lymphodepleting chemotherapy ⓘ |
| routeOfManufacture | centralized manufacturing at specialized facilities ⓘ |
| storage | cryopreserved suspension for intravenous infusion ⓘ |
| targetsDisease |
B-cell acute lymphoblastic leukemia
ⓘ
DLBCL arising from follicular lymphoma ⓘ diffuse large B-cell lymphoma ⓘ
linked to:
non-Hodgkin lymphoma
follicular lymphoma ⓘ high-grade B-cell lymphoma ⓘ |
| therapyType |
immunotherapy
ⓘ
personalized medicine ⓘ |
| tradeNameOf |
tisagenlecleucel
ⓘ
linked to:
Kymriah
|
| usesCellType | autologous T lymphocytes ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Kymriah Description of subject: Kymriah is a pioneering CAR-T cell therapy used to treat certain types of blood cancers by genetically modifying a patient’s own immune cells to target and destroy malignant cells.
Referenced by (6)
Full triples — surface form annotated when it differs from this entity's canonical label.